- Home
- APRE vs BOLT Comparison
APRE vs BOLT Comparison
Compare APRE & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- BOLT
- Stock Information
- Founded
- APRE 2006
- BOLT 2015
- Country
- APRE United States
- BOLT United States
- Employees
- APRE N/A
- BOLT N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- BOLT Health Care
- Exchange
- APRE Nasdaq
- BOLT Nasdaq
- Market Cap
- APRE 9.4M
- BOLT 9.4M
- IPO Year
- APRE 2019
- BOLT 2021
- Fundamental
- Price
- APRE $1.55
- BOLT $5.19
- Analyst Decision
- APRE Strong Buy
- BOLT Buy
- Analyst Count
- APRE 1
- BOLT 3
- Target Price
- APRE $20.00
- BOLT $47.50
- AVG Volume (30 Days)
- APRE 33.0K
- BOLT 14.4K
- Earning Date
- APRE 11-06-2025
- BOLT 08-14-2025
- Dividend Yield
- APRE N/A
- BOLT N/A
- EPS Growth
- APRE N/A
- BOLT N/A
- EPS
- APRE N/A
- BOLT N/A
- Revenue
- APRE $841,012.00
- BOLT $4,167,000.00
- Revenue This Year
- APRE N/A
- BOLT N/A
- Revenue Next Year
- APRE N/A
- BOLT N/A
- P/E Ratio
- APRE N/A
- BOLT N/A
- Revenue Growth
- APRE N/A
- BOLT N/A
- 52 Week Low
- APRE $1.41
- BOLT $4.59
- 52 Week High
- APRE $5.01
- BOLT $14.36
- Technical
- Relative Strength Index (RSI)
- APRE 42.03
- BOLT 46.64
- Support Level
- APRE $1.49
- BOLT $4.81
- Resistance Level
- APRE $1.65
- BOLT $5.28
- Average True Range (ATR)
- APRE 0.08
- BOLT 0.26
- MACD
- APRE -0.01
- BOLT 0.01
- Stochastic Oscillator
- APRE 23.08
- BOLT 70.26
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.